We found that the levels of HIF-1α were reduced in ALL cells treated with DFO, and prolyl hydroxylase domain enzyme-2 (PHD-2) expression was increased, whose effects were reversed by Dex treatment. The gene discussed is EGLN1; the disease is acute lymphoblastic leukemia.